News from

Immunology

Reset All Filters
176 Results
Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors
action-schematic-of-t-cell-destroying-a-cancer-cell

Representation of a T cell destroying a cancer cell

Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors

A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology for experimental approaches in lung cancer and mesothelioma.

Penn Today Staff

Discovering a single cell that leads to relapse
leukemic_cell

Discovering a single cell that leads to relapse

Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia.

Penn Today Staff

CAR T cell therapy receives approval for use across European Union
car t flash mob

Folks from the Abramson Cancer Center celebrate Kymriah’s initial approval by the U.S. Food and Drug Administration in August 2017.

CAR T cell therapy receives approval for use across European Union

The European Commission has approved a personalized cellular therapy developed at the Abramson Cancer Center, making it the first CAR T cell therapy permitted for use in the European Union in two distinct indications.

Penn Today Staff

Cancer cells send out ‘drones’ to battle the immune system from afar
Guo cancer drones

Like drones heading for battle, cancer cells emit vesicles containing immunity-suppressing proteins to tamp down T cell responses at sites throughout the body. (Image: Kelsey Burke)

Cancer cells send out ‘drones’ to battle the immune system from afar

Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition, but only for some patients. Researchers uncovered a novel mechanism by which tumors suppress the immune system, raising the possibility that a straightforward blood test could predict which patients could respond to immunotherapy.